Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.64 |
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL522929 | 0.90 | EGLN1 (0.61) | EGLN1EGLN2 | |
| SCHEMBL30537078 | 0.90 | EGLN1 (0.61) | EGLN1EGLN2 | |
| SCHEMBL15268792 | 0.89 | EGLN2 (0.63) | EGLN1EGLN2 | |
| Hydrochloric Acid SCHEMBL22588812 | 0.88 | EGLN1 (0.53) | EGLN1EGLN2PTGS2 | |
| SCHEMBL31238805 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL29898493 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL15268823 | 0.87 | EGLN1 (0.68) | EGLN1EGLN2 | |
| SCHEMBL1656596 | 0.86 | GABRA1 (0.59) | EGLN1EGLN2 | |
| SCHEMBL22493050 | 0.86 | EGLN1 (0.51) | EGLN1EGLN2PTGS2 | |
| Ethyl Acetate SCHEMBL28993795 | 0.86 | EGLN1 (0.59) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-112300073-B | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2023-09-29 | — | — | CN | claimed |
| CN-117946003-A | Roflumilast intermediate and preparation method thereof | 成都倍特药业股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | JUMPCAN (SHANGHAI) MEDICAL TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| CN-116903532-A | Preparation method of roflumilast | 珠海优润医药科技有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-112300073-B | Preparation method of isoquinoline derivative | 江西同和药业股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116655532-A | Roflumilast intermediate and preparation method thereof | 成都倍特药业股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4169906-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | Jumpcan (Shanghai) Medical Technology Co., Ltd (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115594631-A | Rosemastat key intermediate and preparation method of Rosemastat intermediate | 安徽省庆云医药股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGLN1 7/4885EGLN2 3/4885PTGS2 130/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885EGLN2 3/4885PTGS2 245/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | EGLN1 7/4885EGLN2 3/4885PTGS2 245/4885 |
| US-20240018109-A1 | METHOD FOR SYNTHESIS OF ROXADUSTAT AND INTERMEDIATE THEREOF, AND INTERMEDIATE THEREOF | SRM, SMS, SMOX | EGLN1 914/4885EGLN2 1105/4885PTGS2 2003/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | EGLN1 16/4885EGLN2 4/4885PTGS2 322/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | EGLN1 7/4885EGLN2 5/4885PTGS2 142/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | EGLN1 12/4885EGLN2 5/4885PTGS2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.